Health Condition 1: M329- Systemic lupus erythematosus, unspecified
Conditions
Interventions
Intervention1: Oral Prednisolone: Systemic corticosteroids are considered as mainstay of therapy in SLE
patients owing to their anti-inflammatory and immunosuppressive
properties. Therapy will be star
Sponsors
IMS and SUM Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years and above with SLEDAI score more than 10 fulfilling the EULAR criteria
Exclusion criteria
Exclusion criteria: 1. Patients on any treatment within last 3 months 2. Patients having features of other connective tissue diseases 3. Patients with other autoimmune conditions 4. Patients with pre-existing chronic renal failure, previous malignancy, and liver dysfunction, within six months prior to randomization. 5. Patients with previously documented severe toxicity to immunosuppressive drugs. 6. Patients with active acute or chronic infections. 7. Pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical assessment SLAM-R score Routine investigations (Complete Blood count, Liver function tests, Renal function tests, Urine routine microscopy)Timepoint: At Week 4, 8, 12, 16, 20, and 24. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects due to the drugs if anyTimepoint: At the end of 24 weeks | — |
Countries
India
Contacts
Public ContactDr Asritha C V V
IMS and SUM Hospital
Outcome results
None listed